Upstream & Downstream Processing

Poseida joins Cellares’ early-access cell therapy tech program

Cellares Corporation has added a third firm to its early-stage partnership program, giving Poseida Therapeutics access to its closed and automated cell therapy manufacturing platform. Californian firm Cellares is looking to overcome limitations in current advanced therapy manufacturing through the development of its manufacturing platform, the Cell Shuttle. The Cell Shuttle is a modular and automated solution comprising hardware, software, robotics and consumables and according to the firm is capable of producing 10 patient doses simultaneously. Since 2020, the firm…

Chinese CDMOs eye advanced therapies and global markets

Univercells Technologies says traditional small molecule Chinese CDMOs are rapidly expanding into the cell and gene therapy space as it partners with viral vector producer VectorBuilder. The partnership will see Univercells Technologies – a bioprocess technology firm under KKR’s Gamma Biosciences umbrella – work with VectorBuilder’s manufacturing center in Guangzhou, China to develop and optimize platform processes for the production of custom viral vectors for both cell and gene therapies and vaccine applications. “Through this partnership, both parties will leverage…

Thermo Fisher opens Korean bioprocess center

The Bioprocess Design Center (BDC) in Incheon, Korea will offer support to the region’s continually growing biomanufacturing industry, says Thermo Fisher. The Songdo, Incheon BDC opened its doors earlier this month with the aim “to help enhance the competitiveness of the Korean bio industry,” Scott Song, director of BioProduction and Laboratory Chemical at Thermo Fisher Scientific, said during a promotional video announcing the opening of the site. “The BDC will play a pivotal role in realizing Thermo Fisher Scientific’s vision…

Exothera selects Pall for suspension-based manufacturing contract

Pall will equip Exothera’s expanded facilities in Belgium with a suspension-based manufacturing platform of up to 2,000 L to support the CDMO’s viral vector ambitions. Contract development and manufacturing organization (CDMO) Exothera was launched in March 2020 by Belgium-based bioprocess tech firm Univercells, to offer cell and gene therapy developers process development and viral vector manufacturing. The firm is expanding its two facilities in Jumet, about 25 km south of Brussels, and has selected bioprocess vendor Pall Corporation to equip…

Sartorius bolsters CGT portfolio with $118m stake in CellGenix

Sartorius has acquired a majority stake in CellGenix for $118 million, expanding its cell and gene therapy portfolio. Sartorius has acquired 51% of reagent manufacturing firm CellGenix for around $118 million in cash with plans to buy the remaining shares in 2023 and 2026. The firm anticipates that the acquisition will expand its cell and gene therapy portfolio through the addition of cytokines and media. “CellGenix has an excellent reputation on the market and brings in high technological expertise and…

Cytiva doubles liquid cell culture media capacity with Intermountain bolt-on

The latest acquisition by Cytiva sees it add Intermountain Life Sciences, gaining a buffer and cell culture media manufacturing site in Utah. Terms of the deal have not been disclosed, but Danaher Corporation subsidiary Cytiva has added a 25,000+ square-foot facility in Salt Lake City, Utah. The site can produce 60,000 L/day of Water for Injection (WFI) and formulation lot sizes to 14,000 L, and will significantly expand Cytiva’s bioprocessing offering, said Olivier Loeillot, VP of Cytiva. “This acquisition is…

Repligen buys French filtration firm Polymem

Repligen Corporation has continued its M&A spree with the acquisition of hollow fiber technology firm Polymem. The deal, once complete, will see Repligen add Toulouse, France based ultra and microfiltration tech firm Polymem to its bioprocess portfolio. Polymem was established in 1997 by two engineers specializing in hollow fiber membrane manufacturing and has built itself up into a firm servicing numerous industries, including the biomanufacturing sector. “The acquisition significantly expands our hollow fiber membrane and module production capabilities and adds…

Enzymatic DNA printer will speed R&D and COVID testing, says DNA Script

DNA Script has launched a benchtop nucleic acid printer it claims will accelerate molecular biology, genomic research, and even COVID-19 testing. The Paris, France firm unveiled Syntax this month, describing it as a fully integrated, automated printer that is able to synthesize 96 DNA oligonucleotides in parallel, comprised of up to 60 nucleotides in length. The technology uses enzymes to synthesize the DNA molecules which – unlike traditional phosphoramidite chemistry based approaches – accelerates and optimizes production and eliminates the…

Sepragen skids to help Serum Institute ramp up vaccine production

Sepragen has delivered two chromatography skids to the Serum Institute of India to help increase monthly production of COVID-19 vaccines from 40 million to 200 million doses. Bioprocess equipment manufacturer Sepragen Corporation recently shipped out two 125 liters/minute QuantaSep chromatography skids, with integrated inline buffer blending capabilities, to the Serum Institute, located in Pune, India. “These skids will allow the vaccine manufacturer to increase their production from 40 million doses per month to 200 million doses per month,” a Sepragen…

Cytiva looks to mechanistic modeling in GoSilico deal

Cytiva says the acquisition of scientific software maker GoSilico will boost its position of leadership in the chromatography and process development spaces. The deal, financials of which have not been divulged, sees vendor Cytiva acquire Germany’s GoSilico, adding a portfolio of scientific software based on mechanistic modeling for use in bioprocessing functions. “In the simplest of terms, mechanistic modeling uses software to model a process and predict how something is going to respond – think weather forecasting,” Olivier Loeillot, VP…